Pharmaceutical US neuroscience drug developer Biohaven Pharmaceutical’s shares were barely changed yesterday, despite disclosing top-line results from a Phase III clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in patients with spinocerebellar ataxia (SCA), that did not reach statistical significance in the overall SCA population as there was less than expected disease progression over the course of the study. 24 May 2022